Clinical Trial Update: Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pegfilgrastim given on Day +3 versus Day +1 after salvage chemotherapy in patients with refractory or relapsed aggressive lymphoma. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Pegfilgrastim (pegfilgrastim)

Snippet

Sponsor: Rabin Medical Center | Conditions: Lymphoma, Neutropenia | Phase 3 | Status: UNKNOWN